切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2019, Vol. 13 ›› Issue (06) : 370 -373. doi: 10.3877/cma.j.issn.1674-3253.2019.06.003

所属专题： 经典病例； 经典病例； 文献；

病例研究·（最强挑战赛优秀病例）

转移性前列腺癌患者一例综合诊治报道并文献复习
杨春光1, 李拔森2, 梅齐3, 胡志全1,†()   
  1. 1. 430000　武汉，华中科技大学同济医学院附属同济医院泌尿外科
    2. 430000　武汉，华中科技大学同济医学院附属同济医院放射科
    3. 430000　武汉，华中科技大学同济医学院附属同济医院肿瘤科
  • 收稿日期:2019-02-11 出版日期:2019-12-01
  • 通信作者: 胡志全
  • 基金资助:
    国家自然科学基金(81702989)

The diagnosis and treatment of metastatic prostate cancer: a case repot and review of the literature

Chunguang Yang1, Basen Li2, Qi Mei3, Zhiquan Hu1,†()   

  1. 1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
    2. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
    3. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
  • Received:2019-02-11 Published:2019-12-01
  • Corresponding author: Zhiquan Hu
  • About author:
    Corresponding author: Hu Zhiquan, Email :
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨春光, 李拔森, 梅齐, 胡志全. 转移性前列腺癌患者一例综合诊治报道并文献复习[J]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(06): 370-373.

Chunguang Yang, Basen Li, Qi Mei, Zhiquan Hu. The diagnosis and treatment of metastatic prostate cancer: a case repot and review of the literature[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(06): 370-373.

目的

探讨转移性前列腺癌不同诊断治疗手段的选择和时机。

方法

回顾性分析1例转移性前列腺癌患者的临床资料，复习相关文献并予以讨论。患者，男，65岁，因"耻骨区疼痛伴尿频3月"入院。血PSA>1 000 μg/L。前列腺穿刺活检：双侧均为前列腺腺癌，Gleason评分8分（4+4），临床分期T4N0M1b。

结果

患者接受了去势+比卡鲁胺治疗17个月后进展为去势抵抗性前列腺癌，阿比特龙治疗原发耐药，行基因检测后接受了盆腔放疗和多西他赛化疗，随后病情缓解。

结论

对于转移性前列腺癌患者，内分泌治疗是综合治疗的基石，局部放疗和多西他赛化疗有利于缓解临床症状和延长患者生存期，基因检测对个体化治疗方案的制定有一定指导价值。

关键词: 前列腺癌, 转移性, 多模式治疗, 基因检测, 化疗
Objective

To explore the choices and timing of treatment regimens of metastatic prostate cancer.

Methods

The clinical data of a patient of metastatic prostate cancer was reported. The patient, aged 65 years, was admitted to hospital with pubic region pain and urinary frequency and dysuria for 3 months. Serum total prostate specific antigen (PSA) was more than 1 000 μg/L. So prostate biopsy was performed and Gleason score was 4+4, the clinical stage was T4N0M1b.

Results

The patient underwent combined androgen blockade (castration and bicalutamide) for 17 months. After progressing to castration-resistant prostate cancer (CRPC), the patient showed primary resistance to abiraterone. At the prompt of the genetic test results, the patient received pelvic radiotherapy and docetaxel chemotherapy, showing partial response.

Conclusions

For patients with metastatic prostate cancer, endocrine therapy is the cornerstone of comprehensive treatment. Local radiotherapy and docetaxel chemotherapy are beneficial to alleviate clinical symptoms and prolong the survival of patients. Genetic testing may guide individualized treatment plan.

Key words: Prostate cancer, Metastasis, Multi-modal therapy, Genetic testing, Chemotherapy
图1 2016年6月至2018年11月经各种治疗后血t-PSA水平
表1 基于二代测序技术的基因检测所示的本例患者基因突变
基因 位置 碱基变异 氨基酸变化 突变丰度 突变类型
TP53 chr17:7578461 c.469G>T p.Val157Phe 9.87% 错义突变
NFE2L2 chr2:178096576-178096578 c.753_755delGGA p.Glu251del 13.56% 非移码缺失
KMT2D chr12:49443623 c.3748C>G p.Pro1250Ala 11.36% 错义突变
FAT1 chr4:187629940 c.1042T>C p.Ser348Pro 8.75% 错义突变
[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[3]
Sartor O, de Bono JS. Metastatic prostate cancer[J]. N Engl J Med, 2018, 378(7): 645-657.
[4]
Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review[J]. Urology, 2001, 57(4): 727-732.
[5]
Chen XQ, Huang Y, Li X, et al. Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: A retrospective clinical experience from a chinese medical centre[J]. Asian J androl, 2010, 12(5): 718-727.
[6]
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (getug-afu 15): A randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(2): 149-158.
[7]
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J]. N Engl J Med, 2015, 373(8): 737-746.
[8]
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (stampede): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J]. Lancet, 2016, 387(10024): 1163-1177.
[9]
Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: A seer-medicare analysis[J].J Urol, 2015, 194(2): 378-385.
[10]
Loppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: A national cancer data base analysis[J]. Eur Urol, 2017, 72(1): 14-19.
[11]
Aydemir H, Kumsar S. Re: Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study: A. Heidenreich, d. Pfister and d. Porres j urol 2015, 193: 832-838[J]. J Urol, 2015, 194(3): 853-855.
[12]
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer[J]. N Engl J Med, 2017, 377(4): 352-360.
[13]
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (cou-aa-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol, 2015, 16(2): 152-160.
[14]
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15): 1502-1512.
[15]
de Bono JS, Smith MR, Saad F, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Post hoc analysis of cou-aa-302[J]. Eur Urol, 2017, 71(4): 656-664.
[16]
Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology[J]. Eur Urol, 2019, 75(1): 88-99.
[17]
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
[18]
Giri VN, Knudsen KE, Kelly WK, et al. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017[J]. J Clin Oncol, 2018, 36(4): 414-424.
[19]
Burgio SL, Conteduca V, Rudnas B, et al. Psa flare with abiraterone in patients with metastatic castration-resistant prostate cancer[J]. Clin Genitourin Cancer, 2015, 13(1):39-43.
[20]
Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mrna detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide[J]. J Clin Oncol, 2017, 35(19): 2149-2156.
[21]
Maughan BL, Guedes LB, Boucher K, et al. P53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer[J]. Prostate Cancer Prostatic Dis, 2018, 21(2): 260-268.
[22]
Zhou S, Ye W, Shao Q, et al. Nrf2 is a potential therapeutic target in radioresistance in human cancer[J]. Crit Rev Oncol Hematol, 2013, 88(3): 706-715.
[23]
Sadeghi MR, Jeddi F, Soozangar N, et al. The role of nrf2-keap1 axis in colorectal cancer, progression, and chemoresistance[J]. Tumour Biol, 2017, 39(6): 1010428317705510.
[1] 方晔, 谢晓红, 罗辉. 品管圈在提高前列腺癌穿刺检出率中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 722-727.
[2] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[3] 王雪菲, 海琳悦, 李立方, 肖春花. Luminal A型乳腺癌的内分泌治疗与化疗[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 294-300.
[4] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[5] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[6] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[7] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[8] 樊丽超, 郭瑾瑛, 陈鑫. 野生型RET与RET/PTC融合基因检测对甲状腺乳头状癌中央区淋巴结清扫的指导意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 631-635.
[9] 汪洋, 李志鹏, 王可兵. 上尿路尿路上皮癌术后预防性膀胱灌注化疗的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 649-652.
[10] 李全喜, 唐辉军, 张健生, 杨飞. 基于MUSE-DWI与SS-DWI技术在前列腺癌图像中的对比研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 553-557.
[11] 梅津熠, 王燕, 瞿旻, 董振阳, 周增辉, 沈显琦, 李嘉伦, 高旭. 机器人前列腺癌根治术中"膀胱外中叶"的处理[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 429-433.
[12] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[13] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[14] 王苏贵, 皇立媛, 姜福金, 吴自余, 张先云, 李强, 严大理. 异质性细胞核核糖蛋白A2B1在前列腺癌中的作用及其靶向中药活性成分筛选研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 731-736.
[15] 牛文博, 吴凤鹏, 刘月平, 周超熙, 张娟, 胡旭华, 李保坤, 王贵英. 新辅助放化疗对局部进展期直肠癌疗效及肿瘤免疫微环境变化的研究[J]. 中华临床医师杂志(电子版), 2023, 17(05): 519-523.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号